ARGX logo

argenx SE American Depositary Shares


ARGX: Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.


Show ARGX Financials

Consumer Interest
SEC Filings

Recent trades of ARGX by members of U.S. Congress

Recently reported changes by institutional investors

Quarterly net insider trading by ARGX's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of ARGX in WallStreetBets Daily Discussion


Recent insights relating to ARGX

CNBC Recommendations

Recent picks made for ARGX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ARGX

Corporate Flights

Flights by private jets registered to ARGX